Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 186 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo to Methotrexate Clear all
Completed Phase 2 Interventional Results available

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

NCT03233230
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Phoenix, Arizona • San Leandro, California • DeBary, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

NCT01359943
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
secukinumab (AIN457), placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 2, 2026, 4:09 AM EDT
Recruiting Phase 2 Interventional

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

NCT04380740
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Placebo, Abatacept
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

NCT00665925
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib disodium (R935788), Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
La Jolla, California • Palm Desert, California • Hamden, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

NCT00882024
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
Tranilast, Placebo
Drug
Lead sponsor
Nuon Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Mesa, Arizona • Paradise Valley, Arizona • La Jolla, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 2, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis

NCT01710358
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

NCT02833350
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GDC-0853, Adalimumab, Folic Acid, MTX, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00531817
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Permitted DMARDs
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
156
States / cities
Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate

NCT01329991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

NCT01404585
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, BMS-817399
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Palm Desert, California • Sarasota, Florida • Middleburg Heights, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

NCT02983227
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Glendale, Arizona • Covina, California • El Cajon, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 2, 2026, 4:09 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

NCT07280156
View directory record Official record
Conditions
Gout
Interventions
PRX-115, Methotrexate (MTX), PRX-115 placebo, Placebo-Methotrexate
Biological · Drug · Other
Lead sponsor
Protalix
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
26
States / cities
Glendale, Arizona • Little Rock, Arkansas • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy

NCT00316771
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
P38 Inhibitor (4) 150mg, P38 Inhibitor (4) 25mg, P38 Inhibitor (4) 300mg, P38 Inhibitor (4) 50mg, P38 Inhibitor (4) 75mg, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
48
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

NCT02171143
View directory record Official record
Conditions
Rheumatoid Arthritis, Pharmacokinetics of ASP2409
Interventions
ASP2409, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Anniston, Alabama • Costa Mesa, California • Clearwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

NCT00620685
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, PH-797804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

NCT01894516
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

NCT00960440
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

NCT02885181
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GS-9876, Filgotinib, GS-9876 placebo, Filgotinib placebo, Methotrexate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
DeBary, Florida • Sarasota, Florida • Canton, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 1Phase 2 Interventional

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

NCT01009242
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis
Interventions
CDP6038, Placebo IV, Placebo SC, CDP 6038 SC, Methotrexate
Biological · Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Duncansville, Pennsylvania • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

NCT00847613
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 2, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

NCT02862574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Andecaliximab, Placebo, Methotrexate, TNF Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

NCT01359150
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 2, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

NCT02784106
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Billerica, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 2, 2026, 4:09 AM EDT